A regimen of inhaled Technosphere insulin and insulin degludec is just as good as usual care for glycaemic control, new evidence has indicated.
During the study, the team of researchers from the University of Washington in Seattle analysed the effect of a regimen of inhaled Technosphere insulin plus insulin degludec in people using an automated insulin delivery (AID) system.
In addition, they looked at how inhaled Technosphere insulin plus insulin degludec impacts people with type 1 diabetes using multiple daily insulin injections and a continuous glucose monitor.
- Type 1 diabetes treatment is more than counting carbs
- James Norton: Inspiring awareness of Type 1 Diabetes
People with type 1 diabetes across 19 sites took part in the study.
Each participant was randomly assigned to either inhaled Technosphere insulin plus insulin degludec or usual care for 17 weeks.
According to the research, the mean HbA1c was 7.57 ± 0.97 and 7.62 ± 1.06% at baseline and 17 weeks, respectively, in the inhaled Technosphere insulin plus insulin degludec group and 7.59 ± 0.80 and 7.54 ± 0.77%, respectively, in the usual care group.
- Major international study into type 1 diabetes in children drawing to a close
- New treatment to transform type 1 diabetes care
The results state: “From baseline to 17 weeks, improvement in haemoglobin A1c by >0.5% was seen in 12 people in the inhaled Technosphere insulin plus insulin degludec group and in three people in the usual care group.”
The authors added: “While the study results support consideration of inhaled Technosphere insulin plus insulin degludec group as a viable option for people with type 1 diabetes, patient selection with respect to prescribing it is important.”
Read the study here.
